CAMP4 Therapeutics Corp Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $4.2M+546.6% YoYTTM through 30 Jun 2026
Net Income -$107.2MTTM through 30 Jun 2026
Free Cash Flow -$28.7MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Operating Margin | -1,010.1% |
| Net Margin | -2,543.7% |
Returns
-279.3%ROE
-81.8%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio4.70x
Net Debt-$99.2Mnet cash position
Cash & Equivalents$86.4M
Quality Metrics
Altman Z-Score-4.41
Piotroski F-Score2 / 9
FCF Margin-681.2%
Rule of 40-632.4
Earnings-Beat Rate50.0%
Multi-Year Trend
RevenueFY2025: $3.5M
Diluted EPS-$2.31TTMFY2025: $-2.65
Dividend
No dividend
Capital Allocation
Capex Intensity3.1%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Research and Collaboration | $1.3M | +50.8% | View detailsRevenue is expected to be driven primarily by the ongoing strategic collaboration with GSK, which was signed in December 2025 and includes potential milestone payments of up to $440 million. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.